{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00027695", "CSN": null, "TRF": "ORD_1585460_01", "MRN": "26940830", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1290676", "clinicalId": "1292026", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1585460_01", "SampleName": "US1515401.01", "Version": "0", "Sample": {"FM_Id": "ORD_1585460_01", "SampleId": "US1515401.01", "BlockId": "nan", "TRFNumber": "ORD_1585460_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2023_03_13", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "12", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10069", "MRN": "26940830", "FullName": "\u9673\u6587\u97dc", "FirstName": "Wen_Tao", "LastName": "Chen", "SubmittedDiagnosis": "Unknown primary melanoma", "Gender": "Male", "DOB": "1953_07_02", "OrderingMD": "\u9673\u4ead\u5b89", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2023_03_08", "ReceivedDate": "2023-03-23 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Melanoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "5", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "V163L"}, {"geneName": "ATM", "isVUS": "true", "variantName": "R90M"}, {"geneName": "CD22", "isVUS": "true", "variantName": "Y627D"}, {"geneName": "DDR1", "isVUS": "true", "variantName": "V220M"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "A325T"}, {"geneName": "FGFR3", "isVUS": "true", "variantName": "S108G"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "A173P"}, {"geneName": "HDAC1", "isVUS": "true", "variantName": "E461K"}, {"geneName": "NSD3 (WHSC1L1)", "isVUS": "true", "variantName": "A458V"}, {"geneName": "SNCAIP", "isVUS": "true", "variantName": "N482Y"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A562V"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CTNNB1", "Include": "true", "Alterations": {"Alteration": {"Name": "D32N", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "3.21", "isEquivocal": "false", "name": "D32N"}}, "Interpretation": "CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). CTNNB1 exon 3 mutations are activating in that they lead to increased beta_catenin protein stability and activation of the WNT pathway (Anastas and Moon, 2013; 23258168, Fukuchi et al., 1998; 9721853, Kikuchi et al., 2003; 12824913, Takahashi et al., 2006; 16523258, Tanaka et al., 2001; 11731417, Abraham et al., 2002; 11943721, Austinat et al., 2008; 18282277, Wu et al., 2003; 12820959, Provost et al., 2005; 15829978, Polakis, 1999; 10072352, Segditsas and Tomlinson, 2006; 17143297, Barth et al., 1997; 9024698, Harada et al., 1999; 10545105, Hsu et al., 1998; 9671490, Breuhahn et al., 2008; 18491352, Soon et al., 2008; 18515740, Tacon et al., 2011; 21212436, Simon and Hammer, 2012; 22266195, Hirotsu et al., 2016; 26850916). One or more of the CTNNB1 exon 3 mutations seen here are expected to be activating. CTNNB1 mutations have been reported in 0_5% of skin melanomas (cBio_Hodis et al., 2012; 22817889, cBio_Krauthammer et al., 2012; 22842228, cBio_Cancer Genome Atlas Research Network, 2015; 26091043). Beta_catenin activity has been found to decrease migration of melanoma cells, yet also paradoxically increase melanoma metastasis to the lungs (Gallagher et al., 2012; 22665063, Damsky et al., 2011; 22172720). Loss of beta_catenin, along with a panel of other markers, was found to be a negative prognostic factor in early_stage melanoma (Meyer et al., 2012; 22685558). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a 50% (2/4) PR rate and 25% (1/4) SD rate in patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Clinical trials of gamma_secretase inhibitor nirogacestat have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kasper et al., 2022; ESMO Abstract LBA2, Kummar et al., 2015; ASCO Abstract 10563, Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581).", "Include": "true", "ClinicalTrialNote": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05036226", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of bTMB levels in melanoma are limited (PubMed, Jul 2022). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CTNNB1", "Alteration": "D32N", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "D32N", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "D32N", "Title": "COAST Therapy in Advanced Solid Tumors and Prostate Cancer", "StudyPhase": "PHASE 1/2", "Target": "DDR2, ABL, SRC, KIT, mTOR", "Locations": "South Carolina", "NCTID": "NCT05036226", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "D32N", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}, {"Gene": "CTNNB1", "Alteration": "D32N", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "10679188", "FullCitation": "Biochem. Biophys. Res. Commun. (2000) pmid: 10679188", "Include": "true"}, {"number": "1", "ReferenceId": "23258168", "FullCitation": "Anastas JN, et al. Nat. Rev. Cancer (2013) pmid: 23258168", "Include": "true"}, {"number": "2", "ReferenceId": "9721853", "FullCitation": "Fukuchi T, et al. Cancer Res. (1998) pmid: 9721853", "Include": "true"}, {"number": "3", "ReferenceId": "12824913", "FullCitation": "Cancer Sci. (2003) pmid: 12824913", "Include": "true"}, {"number": "4", "ReferenceId": "16523258", "FullCitation": "Takahashi Y, et al. Virchows Arch. (2006) pmid: 16523258", "Include": "true"}, {"number": "5", "ReferenceId": "11731417", "FullCitation": "Tanaka Y, et al. Cancer Res. (2001) pmid: 11731417", "Include": "true"}, {"number": "6", "ReferenceId": "11943721", "FullCitation": "Abraham SC, et al. Am. J. Pathol. (2002) pmid: 11943721", "Include": "true"}, {"number": "7", "ReferenceId": "18282277", "FullCitation": "Austinat M, et al. Mol. Cancer (2008) pmid: 18282277", "Include": "true"}, {"number": "8", "ReferenceId": "12820959", "FullCitation": "Wu G, et al. Mol. Cell (2003) pmid: 12820959", "Include": "true"}, {"number": "9", "ReferenceId": "15829978", "FullCitation": "Provost E, et al. Oncogene (2005) pmid: 15829978", "Include": "true"}, {"number": "10", "ReferenceId": "10072352", "FullCitation": "Curr. Opin. Genet. Dev. (1999) pmid: 10072352", "Include": "true"}, {"number": "11", "ReferenceId": "17143297", "FullCitation": "Segditsas S, et al. Oncogene (2006) pmid: 17143297", "Include": "true"}, {"number": "12", "ReferenceId": "9024698", "FullCitation": "Barth AI, et al. J. Cell Biol. (1997) pmid: 9024698", "Include": "true"}, {"number": "13", "ReferenceId": "10545105", "FullCitation": "Harada N, et al. EMBO J. (1999) pmid: 10545105", "Include": "true"}, {"number": "14", "ReferenceId": "9671490", "FullCitation": "Hsu SC, et al. Mol. Cell. Biol. (1998) pmid: 9671490", "Include": "true"}, {"number": "15", "ReferenceId": "18491352", "FullCitation": "Breuhahn K, et al. J. Pathol. (2008) pmid: 18491352", "Include": "true"}, {"number": "16", "ReferenceId": "18515740", "FullCitation": "Soon PS, et al. Oncologist (2008) pmid: 18515740", "Include": "true"}, {"number": "17", "ReferenceId": "21212436", "FullCitation": "Tacon LJ, et al. Oncologist (2011) pmid: 21212436", "Include": "true"}, {"number": "18", "ReferenceId": "22266195", "FullCitation": "Simon DP, et al. Mol. Cell. Endocrinol. (2012) pmid: 22266195", "Include": "true"}, {"number": "19", "ReferenceId": "26850916", "FullCitation": "Hirotsu Y, et al. Hepatol. Res. (2016) pmid: 26850916", "Include": "true"}, {"number": "20", "ReferenceId": "22817889", "FullCitation": "Hodis E, et al. Cell (2012) pmid: 22817889", "Include": "true"}, {"number": "21", "ReferenceId": "22842228", "FullCitation": "Krauthammer M, et al. Nat. Genet. (2012) pmid: 22842228", "Include": "true"}, {"number": "22", "ReferenceId": "26091043", "FullCitation": "Cell (2015) pmid: 26091043", "Include": "true"}, {"number": "23", "ReferenceId": "22665063", "FullCitation": "Gallagher SJ, et al. Oncogene (2013) pmid: 22665063", "Include": "true"}, {"number": "24", "ReferenceId": "22172720", "FullCitation": "Damsky WE, et al. Cancer Cell (2011) pmid: 22172720", "Include": "true"}, {"number": "25", "ReferenceId": "22685558", "FullCitation": "Meyer S, et al. PLoS ONE (2012) pmid: 22685558", "Include": "true"}, {"number": "26", "ReferenceId": "30635339", "FullCitation": "Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339", "Include": "true"}, {"number": "27", "ReferenceId": "19403928", "FullCitation": "Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928", "Include": "true"}, {"number": "28", "ReferenceId": "21695255", "FullCitation": "Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255", "Include": "true"}, {"number": "29", "ReferenceId": "18768809", "FullCitation": "Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809", "Include": "true"}, {"number": "30", "ReferenceId": "20347502", "FullCitation": "Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502", "Include": "true"}, {"number": "31", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "32", "ReferenceId": "25624430", "FullCitation": "Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430", "Include": "true"}, {"number": "33", "ReferenceId": "15378020", "FullCitation": "Niida A, et al. Oncogene (2004) pmid: 15378020", "Include": "true"}, {"number": "34", "ReferenceId": "15592430", "FullCitation": "Chamorro MN, et al. EMBO J. (2005) pmid: 15592430", "Include": "true"}, {"number": "35", "ReferenceId": "28574171", "FullCitation": "Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171", "Include": "true"}, {"number": "36", "ReferenceId": "21841793", "FullCitation": "Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793", "Include": "true"}, {"number": "37", "ReferenceId": "23868008", "FullCitation": "Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008", "Include": "true"}, {"number": "38", "ReferenceId": "26349011", "FullCitation": "Shang H, et al. Cancer (2015) pmid: 26349011", "Include": "true"}, {"number": "39", "ReferenceId": "24429522", "FullCitation": "Kode A, et al. Nature (2014) pmid: 24429522", "Include": "true"}, {"number": "40", "ReferenceId": "25231399", "FullCitation": "Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399", "Include": "true"}, {"number": "41", "ReferenceId": "22964660", "FullCitation": "Zhu J, et al. Carcinogenesis (2012) pmid: 22964660", "Include": "true"}, {"number": "42", "ReferenceId": "22356261", "FullCitation": "Kogan Y, et al. Biochem. J. (2012) pmid: 22356261", "Include": "true"}, {"number": "43", "ReferenceId": "22811581", "FullCitation": "Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581", "Include": "true"}, {"number": "44", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "45", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "46", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "47", "ReferenceId": "27623135", "FullCitation": "Kube\u010dek O, et al. Melanoma Res. (2016) pmid: 27623135", "Include": "true"}, {"number": "48", "ReferenceId": "27372860", "FullCitation": "Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860", "Include": "true"}, {"number": "49", "ReferenceId": "7561170", "FullCitation": "Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170", "Include": "true"}, {"number": "50", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "51", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "52", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "53", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "54", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "55", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "56", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "57", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "58", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "59", "ReferenceId": "36512912", "FullCitation": "Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912", "Include": "true"}, {"number": "60", "ReferenceId": "33811152", "FullCitation": "Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152", "Include": "true"}, {"number": "61", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "62", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "63", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "64", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "65", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "66", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "67", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "68", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "69", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "70", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "71", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "72", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "73", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "74", "ReferenceId": "26960397", "FullCitation": "Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397", "Include": "true"}, {"number": "75", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "76", "ReferenceId": "26559571", "FullCitation": "Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571", "Include": "true"}, {"number": "77", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "78", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "79", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "80", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "81", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "82", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "83", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "84", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "85", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "86", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "87", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "88", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "89", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "90", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "91", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "92", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "93", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "94", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "95", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "96", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "97", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_03_20 17:23:08", "OpName": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "12%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary melanoma", "flowcell_analysis": "2000028212", "gender": "male", "pathology_diagnosis": "Melanoma", "pipeline_version": "v3.20.0", "purity_assessment": "9.81", "specimen": "ORD_1585460_01*US1515401.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1585460_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1515401.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5383", "cds_effect": "517G>C", "depth": "2595", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "53.83", "position": "chr20:57415678", "protein_effect": "A173P", "status": "unknown", "strand": "+", "transcript": "NM_016592", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.0022", "cds_effect": "322A>G", "depth": "2281", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "0.22", "position": "chr4:1801193", "protein_effect": "S108G", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.4626", "cds_effect": "1381G>A", "depth": "1442", "equivocal": "false", "functional_effect": "missense", "gene": "HDAC1", "percent_reads": "46.26", "position": "chr1:32798310", "protein_effect": "E461K", "status": "unknown", "strand": "+", "transcript": "NM_004964", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.507", "cds_effect": "973G>A", "depth": "1716", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "50.7", "position": "chr9:97887391", "protein_effect": "A325T", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.4668", "cds_effect": "487G>T", "depth": "2759", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "46.68", "position": "chr2:30143039", "protein_effect": "V163L", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.442", "cds_effect": "1373C>T", "depth": "2208", "equivocal": "false", "functional_effect": "missense", "gene": "WHSC1L1", "percent_reads": "44.2", "position": "chr8:38187104", "protein_effect": "A458V", "status": "unknown", "strand": "_", "transcript": "NM_023034", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.0036", "cds_effect": "1444A>T", "depth": "2250", "equivocal": "false", "functional_effect": "missense", "gene": "SNCAIP", "percent_reads": "0.36", "position": "chr5:121780279", "protein_effect": "N482Y", "status": "unknown", "strand": "+", "transcript": "NM_005460", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.0321", "cds_effect": "94G>A", "depth": "7714", "equivocal": "false", "functional_effect": "missense", "gene": "CTNNB1", "percent_reads": "3.21", "position": "chr3:41266097", "protein_effect": "D32N", "status": "known", "strand": "+", "transcript": "NM_001904", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.0431", "cds_effect": "269G>T", "depth": "8145", "equivocal": "false", "functional_effect": "missense", "gene": "ATM", "percent_reads": "4.31", "position": "chr11:108099988", "protein_effect": "R90M", "status": "unknown", "strand": "+", "transcript": "NM_000051", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.4593", "cds_effect": "658G>A", "depth": "1670", "equivocal": "false", "functional_effect": "missense", "gene": "DDR1", "percent_reads": "45.93", "position": "chr6:30859249", "protein_effect": "V220M", "status": "unknown", "strand": "+", "transcript": "NM_001954", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.0027", "cds_effect": "1879T>G", "depth": "3303", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "0.27", "position": "chr19:35832712", "protein_effect": "Y627D", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}, {"allele_fraction": "0.475", "cds_effect": "1685C>T", "depth": "2619", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "47.5", "position": "chr12:115112055", "protein_effect": "A562V", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.79", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": {"organism": "HHV_4", "reads_per_million": "12", "status": "unknown", "dna_evidence": {"sample": "SQ_US1515401.01_1"}}}}}}}